A Phase 3, Multicenter, Long-term Observational Study Of Subjects From Tanezumab Studies Who Undergo A Total Knee, Hip Or Shoulder Replacement
Phase of Trial: Phase III
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Tanezumab (Primary) ; Celecoxib; Diclofenac; Naproxen
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms TJR-FOLLOW-UP
- Sponsors Pfizer
- 16 Mar 2017 Planned End Date changed from 1 Jul 2019 to 12 Jul 2019.
- 16 Mar 2017 Planned primary completion date changed from 1 Jul 2019 to 12 Jul 2019.
- 04 Nov 2016 Status changed from not yet recruiting to recruiting.